Search Results
101 Results Found for “personalized oncology”
Circulating tumor DNA (ctDNA) has emerged as an innovative and minimally invasive tool in precision oncology. With a short half-life of 30–120 min, ctDNA provides real-time insight into tumor dynamics.1 In early-stage breast cancer, there is growing evidence supporting its potential ...
Join us as leading experts discuss key data from the Plenary, Late-breaking and top oral sessions across each major disease area at ASCO 2026 touchONCOLOGY coverage of ASCO 2026 2026 American Society of Clinical Oncology (ASCO) Annual Meeting brought together the global oncology ...
From adjuvant immunotherapy to microbiome-driven precision medicine, the biggest renal cell carcinoma abstracts presented at ASCO 2026 highlight where the field is heading next, and what may change first. In this round-up, we discuss the key data from four of the meeting’s most important studies, from investigational to late-phase: RAMPART, KEYNOTE-564, CaboNivo in patients with nccRCC and microbiome-based predictive biomarker development in mRCC.
Glioblastoma (GBM) places an enormous emotional and practical burden on both patients and caregivers. At AAN 2026, Dr Jigisha Thakkar et al. explored how cultural and ethnic differences influence preferences for communication and care delivery in neuro-oncology settings. In this Q&A, Dr Thakkar discusses the key takeaways from her study, and how these findings could help shape more individualized approaches to neuro-oncologic care.
The 38th Annual Congress of the European Association of Nuclear Medicine (EANM) in Barcelona brought together over 9,400 participants, marking a major milestone. The meeting highlighted major advances in oncologic imaging and theranostics, with a strong emphasis on precision medicine and combination treatment strategies. Across plenary sessions, debates, and late-breaking discussions, the meeting underscored how nuclear medicine is increasingly central to cancer diagnosis, treatment selection, and therapeutic delivery.
In this Future Leaders interview, Dr Kevin Keane discusses the mentors who shaped his approach to clinically meaningful research, the integration of surgery and innovation in uro-oncology and the collaborative, patient-centred advances set to transform bladder cancer care.
In this Future Leaders interview, Dr Haywood discusses the mentors who shaped her career, the value of combining clinical care with research, and why collaboration and mentorship are essential for the next generation of oncologists.
At EBCC15, Dr Elisa Agostinetto presented compelling evidence that circulating tumor DNA (ctDNA) at completion of neoadjuvant therapy could be a game-changer biomarker for predicting breast cancer relapse. In the Q&A below, Dr. Agostinetto discusses the implications of her findings and the path toward integrating ctDNA into routine clinical practice.
At EAU26, Prof Dickon Hayne presented findings from the ANZUP 1301 (BCG+MM) trial. With global BCG shortages and ongoing challenges around tolerability, the study offers timely insights into how combination intravesical strategies may deliver comparable efficacy while improving patient experience and resource utilisation.
Pancreatic cancer (PC) is the tenth most common cancer in 2024, with 66,440 new cases and 51,570 deaths.1,2Â Globally, the prevalence varies from 10/100,000 cases in the Americas and Europe to 0.9/100,000 cases in South Central Asia and most of Africa.3Â Currently, it has the ...
Emerging strategies in head and neck cancer focus on personalizing therapy and reducing toxicity. ctDNA-guided chemotherapy with pembrolizumab in recurrent HNSCC achieved a 73% response rate, while ozuriftamab vedotin showed promising activity in pretreated HPV-positive OPSCC. Long-term results from the Quarterback trials indicate that reduced-dose chemoradiation after induction chemotherapy maintains durable control in selected patients. These findings support further exploration of molecular-guided, targeted, and de-escalated approaches to optimize outcomes.
February has already been very busy across regulation, clinical research and community awareness - and we're only half way through! See below a round-up of the main breakthroughs and what to look out for during the rest of the month. ...
As we begin 2026, Dr Ana Tecic Vuger (University Hospital for Tumors, Zagreb, Croatia) reflects on the major breakthroughs throughout 2025. The breast cancer community has witnessed transformative progress across the continuum of research and clinical care, from more precise targeted therapies and novel endocrine strategies to advances in biomarker-driven treatment sequencing and survivorship. The major oncology meetings – ASCO 2025, ESMO/ESMO Breast 2025, and the San Antonio Breast Cancer Symposium (SABCS) 2025 – offered a rich tapestry of data that helps shape practice and sharpen research priorities.
Breakthroughs from the 2025 San Antonio Breast Cancer Symposium in oral SERDs, HER2-targeted maintenance therapy, ADCs and next-generation endocrine combinations are reshaping breast cancer care across early and metastatic disease. From practice-changing phase III data to nuanced treatment selection in triple-positive and ESR1-mutant disease, this in-depth report unpacks what the latest trials really mean for clinicians. Register now to read the full analysis and stay ahead of rapidly evolving practice.
Immune checkpoint inhibitors (ICIs) act by blocking inhibitory pathways such as programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1)Â and cytotoxic T lymphocyte-associated antigen 4Â (CTLA-4), thereby restoring T-cell activity and promoting tumour cell destruction.1,2Â The ability of tumours ...
The European Society for Medical Oncology (ESMO) 2025 congress brought over 100 late-breaking abstracts, 250 sessions, 600 expert speakers and 33,800 delegates to Berlin in October. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of oncology practice.
At this year’s ESMO 2025 lung-cancer programme, several large phase II/III studies delivered practice-shaking results across EGFR-mutant, squamous, small-cell and ALK-positive disease. From upfront osimertinib plus chemo to antibody-drug conjugates in chemo-resistant EGFR-mutant disease and adjuvant ALK inhibition, here are the six landmark abstracts clinicians and researchers need to know — and what they could mean for the clinic.
The European Society for Medical Oncology (ESMO) 2025 congress brought over 100 late-breaking abstracts, 250 sessions, 600 expert speakers and 33,800 delegates to Berlin in October. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of oncology practice.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
